McKesson Issues $2 Billion Notes for Acquisition

McKesson ( (MCK) ) just unveiled an update.

On May 30, 2025, McKesson Corporation issued $2 billion in unsecured and unsubordinated notes with varying interest rates due in 2030, 2032, and 2035. The proceeds will fund the acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC, indicating a strategic move to expand its footprint in oncology services.

The most recent analyst rating on (MCK) stock is a Hold with a $540.00 price target. To see the full list of analyst forecasts on McKesson stock, see the MCK Stock Forecast page.

Spark’s Take on MCK Stock

According to Spark, TipRanks’ AI Analyst, MCK is a Outperform.

McKesson’s overall stock score of 72 reflects its strong revenue growth, enhanced profitability, and effective cash flow generation. However, risks from high leverage and negative equity, alongside potential overvaluation, temper the score. The stock’s technical indicators show balanced sentiment, while recent earnings call highlights strong performance but acknowledges strategic uncertainties.

To see Spark’s full report on MCK stock, click here.

More about McKesson

McKesson Corporation operates in the healthcare industry, providing pharmaceuticals and medical supplies. The company focuses on delivering healthcare services and solutions to improve patient care and optimize healthcare systems.

Average Trading Volume: 1,073,813

Technical Sentiment Signal: Buy

Current Market Cap: $89.1B

For detailed information about MCK stock, go to TipRanks’ Stock Analysis page.